AmideBio signs partnership with CU

BOULDER – AmideBio LLC signed a research agreement with the University of Colorado at Boulder to help discover potential treatments for Alzheimer’s disease.

Working with molecular, cellular and developmental biology associate professor Michael Stowell, Boulder-based AmideBio will use a screening process to find compounds that influence the interaction between two proteins thought to be involved in Alzheimer’s disease.

AmideBio will be able to option newly discovered compounds through the collaboration. Those new compounds will hopefully be used in treating Alzheimer’s.

SPONSORED CONTENT

How dispatchable resources enable the clean energy transition

Platte River must prepare for the retirement of 431 megawatts (MW) of dispatchable, coal-fired generation by the end of the decade and address more frequent extreme weather events that can bring dark calms (periods when there is no sun or wind).

“AmideBio’s commitment to our research will help to accelerate the discovery of potential therapeutics for Alzheimer’s by providing both financial support and the large quantities of amyloid peptides needed for screening,” Stowell said in a statement.

In January, the Boulder company licensed technology to develop, manufacture and commercialize peptides using a manufacturing process developed by Stowell.

And in February, the company, which was co-founded by Misha Plam who previously led Bioptix Diagnostics Inc., announced it raised $274,997 in a seed round.